United Kingdom-based AstraZeneca's oncology immunotherapy Imfinzi (durvalumab) has received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC), it was reported yesterday.
Last month, a phase three trial called CASPIAN met its primary endpoint with Imfinzi by delivering a statistically-significant and clinically-meaningful improvement in overall survival for patients suffering from extensive-stage SCLC.
The CASPIAN trial assessed Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy against chemotherapy alone. The drug is also being assessed in limited-stage SCLC after concurrent chemoradiation therapy in a phase three trial, called ADRIATIC. Imfinzi is a human monoclonal antibody, which has been designed to target the PD-1/PD-L1 pathway.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study